Schering-Plough buys Organon for $14.4B
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Schering-Plough |
Akzo Nobel |
$14.4B sale |
The deal gives Schering-Plough the world's third-largest maker of birth control pills and an overnight boost of 50 percent to its revenue line. |
|
Merck |
Avalon Pharmaceuticals |
$200M development deal |
Avalon agreed to use its technology to identify a compound that can block the activity of an undisclosed protein involved in the development of cancer. |
|
Eli Lilly |
Hypnion |
Buyout |
Eli Lilly is buying Hypnion, a Lexington, MA-based biotech company that has specialized in developing sleep disorder drugs. |
|
Takeda Pharmaceutical |
Paradigm Therapeutics |
Buyout |
Paradigm has a pipeline of targets for pain, central nervous system disorders, prostate and breast cancer, diabetes and obesity. |
|
Oxford BioMedica |
Oxxon Therapeutics |
Buyout |
Oxxon Therapeutics is being acquired by Oxford BioMedica, which has been developing gene-based therapeutic vaccines for cancer and neurotherapy. |
|
Organon |
Acrux |
Development deal |
Australia-based drug delivery company Acrux has teamed up with Organon to develop and market contraceptives delivered through the skin using Acrux's spray technology. |